SpringerLink
Log in

Secondary malignancy in patients with sporadic neuroendocrine neoplasia

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

The incidence of neuroendocrine neoplasias (NENs), especially of the gastro-entero-pancreatic (GEP), system relatively increased over the past decades, as a result of advanced diagnostic tools, a better clinical awareness, and distinguished pathological diagnostic recognition. Previous reports hypothesized an increased risk for secondary malignancies in patients with NEN especially in GEP–NENs. The present study was designed to investigate the coincidence of NENs and secondary malignancies in a large patient collective. A retrospective analysis was performed on 161 patients (85 female and 76 male) with NEN of various origins. Clinical data of these patients, different classification systems (TNM/WHO), proliferations-based grading, and clinical follow-up were collected and analyzed. Out of 143 patients with a sporadic NEN, 15 (10.49 %) patients were identified with secondary malignant tumors. Median age at the time of the primary operation for NEN was 65 years, whereas the median age of initial diagnosis of associated tumors was 59 years. Mean follow-up time was 61 months. The risk of develo** a secondary malignancy was most elevated for patients with an NEN of the lung, the stomach, and the ileum (60, 50 and 20 %, respectively). The spectrum of secondary malignancies included various types of cancer. Kaplan–Meier survival analysis shows a difference suggesting that patients with a secondary malignancy demonstrate a worse survival compared to patients without a secondary tumor; no significance was detected (p = 0.349). Our data suggest that secondary malignancies in patients with NEN’s especially in GEP–NENs are found more frequently than in general population. Therefore, patients with NEN need a continuous and detailed follow-up. The reason for the increased incidence of secondary malignancies in patients with NENs remains to be elucidated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. D. Dhall, R. Mertens, C. Bresee, R. Parakh, H.L. Wang, M. Li et al., Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors. Hum. Pathol. 43(4), 489–495 (2012)

    Article  PubMed  CAS  Google Scholar 

  2. J. Strosberg, A. Nasir, D. Coppola, M. Wick, L. Kvols, Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum. Pathol. 40(9), 1262–1268 (2009)

    Article  PubMed  Google Scholar 

  3. M. Krausch, F. Kroepil, N. Lehwald, A. Lachenmayer, M. Schott, M. Anlauf, K. Cupisti, W.T. Knoefel, A. Raffel, Notch 1 tumor expression is lacking in highly proliferative pancreatic neuroendocrine tumors. Endocrine (2012). doi:10.1007/s12020-012-9850-5

  4. M. Anlauf, N. Garbrecht, J. Bauersfeld, A. Schmitt, T. Henopp, P. Komminoth, P.U. Heitz, A. Perren, G. Klöppel, Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch. 451(Suppl 1), S29–S38 (2007)

    Article  PubMed  Google Scholar 

  5. C.S. Landry, C.R. Scoggins, K.M. McMasters, R.C. Martin 2nd, Management of hepatic metastasis of gastrointestinal carcinoid tumors. J. Surg. Oncol. 97(3), 253–258 (2008)

    Article  PubMed  Google Scholar 

  6. F. Costa, E. Domenichini, G. Garavito, R. Medrano, G. Mendez, J. O’Connor, W. Rojas, S. Torres, R.N. Younes, G. Delle Fave, K. Oberg, Management of neuroendocrine tumors: a meeting of experts from Latin America. Neuroendocrinology 88(3), 235–242 (2008)

    Article  PubMed  CAS  Google Scholar 

  7. K. Müssig, M.O. Oksüz, K. Dudziak, B. Ueberberg, M. Wehrmann, M. Horger, S. Schulz, H.U. Häring, C. Pfannenberg, R. Bares, B. Gallwitz, S. Petersenn, Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68 Ga]-DOTATOC PET/CT in neuroendocrine tumors. Horm. Metab. Res. 42(8), 599–606 (2010)

    Article  PubMed  Google Scholar 

  8. K.L. Yim, Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours. Endocrine 40(2), 181–186 (2011)

    Article  PubMed  CAS  Google Scholar 

  9. I.M. Modlin, S.F. Moss, B.I. Gustafsson, B. Lawrence, S. Schimmack, M. Kidd, The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant. Langenbecks Arch. Surg. 396(8), 1145–1156 (2011)

    Article  PubMed  Google Scholar 

  10. I.M. Modlin, S.F. Moss, D.C. Chung, R.T. Jensen, E. Snyderwine, Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J. Natl. Cancer Inst. 100(18), 1282–1289 (2008)

    Article  PubMed  Google Scholar 

  11. Krystallenia I. Alexandraki, Gregory Kaltsas, Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy. Endocrine 41, 40–52 (2012)

    Article  PubMed  CAS  Google Scholar 

  12. F. Ehehalt, H.D. Saeger, C.M. Schmidt, R. Grutzmann, Neuroendocrine tumors of the pancreas. Oncologist. 14(5), 456–467 (2009)

    Article  PubMed  CAS  Google Scholar 

  13. A. Faggiano, P. Ferolla, F. Grimaldi, D. Campana, M. Manzoni, M.V. Davi et al., Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian Epidemiological study: THE NET MANAGEMENT STUDY. J. Endocrinol. Investig. 35(9), 817–823 (2012)

    CAS  Google Scholar 

  14. S. Massironi, V. Sciola, M. Peracchi, C. Ciafardini, M.P. Spampatti, D. Conte, Neuroendocrine tumors of the gastro-entero-pancreatic system. World J. Gastroenterol. 14(35), 5377–5384 (2008)

    Article  PubMed  Google Scholar 

  15. G. Rindi, C. Bordi, Endocrine tumours of the gastrointestinal tract: aetiology, molecular pathogenesis and genetics. Best Pract. Res. Clin. Gastroenterol. 19(4), 519–534 (2005)

    Article  PubMed  CAS  Google Scholar 

  16. R.G. Robertson, W.J. Geiger, N.B. Davis, Carcinoid tumors. Am. Fam. Physician 74(3), 429–434 (2006)

    PubMed  Google Scholar 

  17. J.C. Yao, M. Hassan, A. Phan, C. Dagohoy, C. Leary, J.E. Mares et al., One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26(18), 3063–3072 (2008)

    Article  PubMed  Google Scholar 

  18. G. Kloppel, G. Rindi, M. Anlauf, A. Perren, P. Komminoth, Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch. 451(Suppl 1), S9–S27 (2007)

    Article  PubMed  Google Scholar 

  19. G. Rindi, G. Kloppel, A. Couvelard, P. Komminoth, M. Korner, J.M. Lopes et al., TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 451(4), 757–762 (2007)

    Article  PubMed  CAS  Google Scholar 

  20. G. Rindi, G. Kloppel, H. Alhman, M. Caplin, A. Couvelard, W.W. de Herder et al., TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 449(4), 395–401 (2006)

    Article  PubMed  CAS  Google Scholar 

  21. J.S. de Vries, S. de Vries, D.C. Aronson, D.K. Bosman, E.A. Rauws, A. Bosma et al., Choledochal cysts: age of presentation, symptoms, and late complications related to Todani’s classification. J. Pediatr. Surg. 37(11), 1568–1573 (2002)

    Article  PubMed  Google Scholar 

  22. M. Anlauf, P. Gerlach, M. Schott, A. Raffel, M. Krausch, W.T. Knoefel et al., Pathology of neuroendocrine neoplasms. Chirurg 82(7), 567–573 (2011)

    Article  PubMed  CAS  Google Scholar 

  23. F.C.F. Bosman, R. Hruban, N. Theise, WHO Classification of Tumours of the Digestive System (IARC Press, Lyon, France, 2010)

    Google Scholar 

  24. M. Brune, B. Gerdes, M. Koller, M. Rothmund, Neuroendocrine tumors of the gastrointestinal tract (NETGI) and second primary malignancies—which is dominant? Dtsch. Med. Wochenschr. 128(46), 2413–2417 (2003)

    Article  PubMed  CAS  Google Scholar 

  25. V. Fendrich, J. Waldmann, D.K. Bartsch, K. Schlosser, M. Rothmund, B. Gerdes, Multiple primary malignancies in patients with sporadic pancreatic endocrine tumors. J. Surg. Oncol. 97(7), 592–595 (2008)

    Article  PubMed  Google Scholar 

  26. J.D. Godwin 2nd, Carcinoid tumors. An analysis of 2,837 cases. Cancer 36(2), 560–569 (1975)

    Article  PubMed  Google Scholar 

  27. I.M. Modlin, A. Sandor, An analysis of 8305 cases of carcinoid tumors. Cancer 79(4), 813–829 (1997)

    Article  PubMed  CAS  Google Scholar 

  28. M.B. Niederle, B. Niederle, Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation. Oncologist 16(5), 602–613 (2011)

    Article  PubMed  Google Scholar 

  29. U.F. Pape, U. Berndt, J. Muller-Nordhorn, M. Bohmig, S. Roll, M. Koch et al., Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr. Relat. Cancer 15(4), 1083–1097 (2008)

    Article  PubMed  Google Scholar 

  30. E.A. Perez, L.G. Koniaris, S.E. Snell, J.C. Gutierrez, W.E. Sumner 3rd, D.J. Lee et al., 7201 carcinoids: increasing incidence overall and disproportionate mortality in the elderly. World J. Surg. 31(5), 1022–1030 (2007)

    Article  PubMed  Google Scholar 

  31. R. Prommegger, C. Ensinger, P. Steiner, T. Sauper, C. Profanter, R. Margreiter, Neuroendocrine tumors and second primary malignancy—a relationship with clinical impact? Anticancer Res. 24(2C), 1049–1051 (2004)

    PubMed  Google Scholar 

  32. KO. Shebani, WW. Souba, DM. Finkelstein, PC. Stark, KM. Elgadi, KK. Tanabe, et al., Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann. Surg. 229(6), 815–21, discussion 22–3 (1999)

    Google Scholar 

  33. Y. Kobayashi, H. Arimoto, S. Watanabe, Occurrence of multiple primary cancer at the National Cancer Center Hospital, 1962–1989. Jpn. J. Clin. Oncol. 21(3), 233–251 (1991)

    PubMed  CAS  Google Scholar 

  34. J.T. Flannery, J.D. Boice Jr, S.S. Devesa, R.A. Kleinerman, R.E. Curtis, J.F. Fraumeni Jr, Cancer registration in Connecticut and the study of multiple primary cancers, 1935–1982. Natl. Cancer Inst. Monogr. 68, 13–24 (1985)

    PubMed  CAS  Google Scholar 

  35. B.H. Lang, K.P. Wong, Risk factors for nonsynchronous second primary malignancy and related death in patients with differentiated thyroid carcinoma. Ann. Surg. Oncol. 18(13), 3559–3565 (2011)

    Article  PubMed  Google Scholar 

  36. M.L. Cote, A.S. Wenzlaff, P.A. Philip, A.G. Schwartz, Secondary cancers after a lung carcinoid primary: a population-based analysis. Lung Cancer 52(3), 273–279 (2006)

    Article  PubMed  CAS  Google Scholar 

  37. K.A. Zucker, W.E. Longo, I.M. Modlin, A.J. Bilchik, T.E. Adrian, Malignant diathesis from jejunal-ileal carcinoids. Am. J. Gastroenterol. 84(2), 182–186 (1989)

    PubMed  CAS  Google Scholar 

  38. G.M. Dores, C. Metayer, R.E. Curtis, C.F. Lynch, E.A. Clarke, B. Glimelius et al., Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J. Clin. Oncol. 20(16), 3484–3494 (2002)

    Article  PubMed  Google Scholar 

  39. L.B. Travis, S.D. Fossa, S.J. Schonfeld, M.L. McMaster, C.F. Lynch, H. Storm et al., Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J. Natl. Cancer Inst. 97(18), 1354–1365 (2005)

    Article  PubMed  Google Scholar 

  40. H.M. Schuller, H.P. Witschi, E. Nylen, P.A. Joshi, E. Correa, K.L. Becker, Pathobiology of lung tumors induced in hamsters by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and the modulating effect of hyperoxia. Cancer Res. 50(6), 1960–1965 (1990)

    PubMed  CAS  Google Scholar 

  41. P.J. Taddei, R.M. Howell, S. Krishnan, S.B. Scarboro, D. Mirkovic, W.D. Newhauser, Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma. Phys. Med. Biol. 55(23), 7055–7065 (2010)

    Article  PubMed  Google Scholar 

  42. J.D. Wright, C.M. St Clair, I. Deutsch, Wm Burke, P. Gorrochurn, X. Sun et al., Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer 116(10), 2486–2492 (2010)

    PubMed  Google Scholar 

  43. V. D’Onghia, R. Leoncini, R. Carli, A. Santoro, S. Giglioni, F. Sorbellini et al., Circulating gastrin and ghrelin levels in patients with colorectal cancer: correlation with tumour stage, Helicobacter pylori infection and BMI. Biomed.Pharmacother. 61(2–3), 137–141 (2007)

    Article  PubMed  Google Scholar 

  44. A.S. Takhar, O. Eremin, S.A. Watson, The role of gastrin in colorectal carcinogenesis. Surg. J. Royal Coll. Surg. Edinb. Irel. 2(5), 251–257 (2004)

    CAS  Google Scholar 

  45. R.J. Bold, J. Ishizuka, C.M. Townsend Jr, J.C. Thompson, Gastrin stimulates growth of human colon cancer cells via a receptor other than CCK-A or CCK-B. Biochem. Biophys. Res. Commun. 202(3), 1222–1226 (1994)

    Article  PubMed  CAS  Google Scholar 

  46. C.M. Thorburn, G.D. Friedman, C.J. Dickinson, J.H. Vogelman, N. Orentreich, J. Parsonnet, Gastrin and colorectal cancer: a prospective study. Gastroenterology 115(2), 275–280 (1998)

    Article  PubMed  CAS  Google Scholar 

  47. T.J. Koh, D. Chen, Gastrin as a growth factor in the gastrointestinal tract. Regul. Pept. 93(1–3), 37–44 (2000)

    Article  PubMed  CAS  Google Scholar 

  48. R.J. Bold, J. Ishizuka, C.Z. Yao, C.M. Townsend Jr, J.C. Thompson, Bombesin stimulates in vitro growth of human breast cancer independent of estrogen receptors status. Anticancer Res. 18(6A), 4051–4056 (1998)

    PubMed  CAS  Google Scholar 

  49. F. Cuttitta, D.N. Carney, J. Mulshine, T.W. Moody, J. Fedorko, A. Fischler et al., Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 316(6031), 823–826 (1985)

    Article  PubMed  CAS  Google Scholar 

  50. P. Kuiper, H.W. Verspaget, I. Biemond, E.S. de Jonge-Muller, S. van Eeden, M.L. van Velthuysen et al., Expression and ligand binding of bombesin receptors in pulmonary and intestinal carcinoids. J. Endocrinol. Investig. 34(9), 665–670 (2011)

    CAS  Google Scholar 

  51. I.I. Schnirer, J.C. Yao, J.A. Ajani, Carcinoid—a comprehensive review. Acta Oncol. 42(7), 672–692 (2003)

    Article  PubMed  Google Scholar 

  52. A. Chaudhry, K. Oberg, A. Gobl, C.H. Heldin, K. Funa, Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. Anticancer Res. 14(5B), 2085–2091 (1994)

    PubMed  CAS  Google Scholar 

  53. G. Vitale, P.M. van Koetsveld, W.W. de Herder, K. van der Wansem, J.A. Janssen, A. Colao, G. Lombardi, S.W. Lamberts, L.J. Hofland, Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. Am. J. Physiol. Endocrinol. Metab. 296(3), 559–566 (2009)

    Google Scholar 

  54. R. Hrascan, N. Pecina-Slaus, T.N. Martic, J.F. Colic, K. Gall-Troselj, K. Pavelic et al., Analysis of selected genes in neuroendocrine tumours: insulinomas and phaeochromocytomas. J. Neuroendocrinol. 20(8), 1015–1022 (2008)

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors are grateful to Dipl.-Math. Dr. Dieter Hafner, Institute for Pharmacology and Clinical Pharmacology, Chairman: Univ.-Prof. Dr. med. J. W. Fischer, Heinrich-Heine University Duesseldorf, for his help with the statistical analysis.

Conflict of interest

  We declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Author information

Authors and Affiliations

  1. Department of General, Visceral and Pediatric Surgery, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany

    M. Krausch, A. Raffel, N. Lehwald, A. Krieg, F. Kröpil, K. Cupisti & W. T. Knoefel

  2. Institute of Pathology, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany

    M. Anlauf

  3. Department of Endocrinology Diabetes and Rheumatology, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany

    M. Schott

Authors
  1. M. Krausch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Raffel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Anlauf
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Schott
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Lehwald
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Krieg
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Kröpil
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K. Cupisti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. W. T. Knoefel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Krausch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krausch, M., Raffel, A., Anlauf, M. et al. Secondary malignancy in patients with sporadic neuroendocrine neoplasia. Endocrine 44, 510–516 (2013). https://doi.org/10.1007/s12020-013-9911-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-013-9911-4

Keywords

Search

Navigation